A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
This study has been completed.
Information provided by (Responsible Party):
First received: April 26, 2011
Last updated: February 5, 2015
Last verified: February 2015
This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations in their tumours. Patients were randomized to receive either Tarceva 150 mg orally daily or 3-week cycles of gemcitabine 1250 mg/m^2 intravenously (iv) on Days 1 and 8 plus cisplatin 75 mg/m^2 iv on Day 1.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Multicenter, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva®) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Patients With Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumors|
Resource links provided by NLM:
Drug Information available for: Cisplatin Gemcitabine Gemcitabine hydrochloride Erlotinib hydrochloride ErlotinibU.S. FDA Resources
Further study details as provided by Hoffmann-La Roche:
Primary Outcome Measures:
- Investigator-assessed Duration of Progression-free Survival [ Time Frame: Baseline to the data cut-off date of 20 Jul 2012 (1 year, 4 months) ]The duration of progression-free survival was defined as the time from randomization to disease progression (PD) or death from any cause, whichever occurs first. PD was defined as: (1) At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum). The sum must also demonstrate an absolute increase of at least 5 mm. (2) An unequivocal progression of existing non-target lesions. When the patient has measurable disease, the overall tumor burden must have increased sufficiently to merit discontinuation of therapy. When the patient has only non-measurable disease, the increase in overall disease burden should be comparable in magnitude to the increase that would be required to declare PD for measurable disease. (3) The appearance of new malignant lesions.
Secondary Outcome Measures:
- Percentage of Responders as Assessed by the Investigator [ Time Frame: Baseline to the data cut-off date of 19 Nov 2012 (1 year, 8 months) ]A responder was defined as a participant with either a complete response (CR) or a partial response (PR), as determined using the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. A CR was defined as: (1) The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to < 10 mm. (2) The disappearance of all non-target lesions and normalization of tumor marker levels. All lymph nodes must be non-pathological in size (< 10 mm in the short axis). A PR was defined as: (1) At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (2) The persistence of 1 or more non-target lesion(s) and/or maintenance of tumor marker levels above normal limits.
- Percentage of Participants With Disease Control [ Time Frame: Baseline to the data cut-off date of 19 Nov 2012 (1 year, 8 months) ]A participant with disease control was defined as a participant with either a complete response (CR), a partial response (PR), or stable disease (SD), as determined using RECIST v1.1. A CR was defined as the disappearance of all target lesions (TL). A PR was defined as at least a 30% decrease in the sum of the longest diameter of TLs taking as reference the Baseline sum longest diameter (SLD). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest SLD since treatment started. For non-TLs, SD was defined as the persistence of 1 or more lesions. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since treatment started or the unequivocal progression of existing non-TLs. A SLD for all TLs will be calculated and reported as the Baseline SLD.
- Duration of Response [ Time Frame: Baseline to the data cut-off date of 19 Nov 2012 (1 year, 8 months) ]Duration of response was defined as the time from the first documented complete response (CR) or partial response (PR) to the first documented disease progression (PD) or death, whichever occurs first. A CR was defined as the disappearance of all target lesions (TL). A PR was defined as at least a 30% decrease in the sum of the longest diameter (SLD) of TLs taking as reference the Baseline SLD. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since treatment started or the unequivocal progression of existing non-TLs.
- Overall Survival [ Time Frame: Baseline to the end of the study (3 years, 1 month) ]Overall survival was defined as the time from the date of randomization to the date of death from any cause.
- Safety: Incidence of Adverse Events [ Time Frame: 36 months ]
- Quality of Life: Functional Assessment of Chronic Illness Therapy - Lung (FACIT-L) Questionnaire [ Time Frame: approximately 21 months ]
|Study Start Date:||March 2011|
|Study Completion Date:||April 2014|
|Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.
Erlotinib was supplied as tablets.
Other Name: Tarceva
Active Comparator: Chemotherapy
Participants received gemcitabine 1250 mg/m^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.
Cisplatin and gemcitabine were locally sourced with commercial products.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01342965
Please refer to this study by its ClinicalTrials.gov identifier: NCT01342965
|Beijing, China, 100071|
|Beijing, China, 101149|
|Changchun, China, 130012|
|Chongqing, China, 400038|
|ChongQing, China, 400042|
|Fuzhou, China, 350014|
|Guangzhou, China, 510080|
|Hangzhou, China, 310016|
|Nanjing, China, 210002|
|Shanghai, China, 200030|
|Shanghai, China, 200032|
|Shanghai, China, 200433|
|Shantou, China, 515041|
|Wuhan, China, 430023|
|Xi'an, China, 710061|
|Kelantan, Malaysia, 16150|
|Kuala Lumpur, Malaysia, 50603|
|Kuala Lumpur, Malaysia, 59100|
|Nilai, Malaysia, 71800|
|Pahang, Malaysia, 25100|
|Petaling Jaya, Selangor, Malaysia, 46050|
|Petaling Jaya, Malaysia, 46150|
|Pulau Pinang, Malaysia, 11600|
|Davao, Philippines, 8000|
|Desmarinas City, Philippines, 4114|
|Manila, Philippines, 1000|
|Quezon City, Philippines, 1104|
|San Juan, Philippines, 1500|
Sponsors and Collaborators
|Study Director:||Clinical Trials||Hoffmann-La Roche|